Clinigen Group (CLIGF) Lowered to “Sell” at Zacks Investment Research

Zacks Investment Research lowered shares of Clinigen Group (OTCMKTS:CLIGF) from a buy rating to a sell rating in a research report sent to investors on Tuesday morning, Zacks.com reports.

According to Zacks, “Clinigen Group plc is a pharmaceutical and services company. Its business focuses in areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen Group plc is headquartered in Burton-on-Trent, the United Kingdom. “

Shares of CLIGF opened at $9.87 on Tuesday. Clinigen Group has a 52-week low of $9.87 and a 52-week high of $12.59.

Further Reading: Marijuana Stocks Investing Considerations

Get a free copy of the Zacks research report on Clinigen Group (CLIGF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.